Abstract
Type 2 diabetes is increasing in prevalence and it is estimated that three million individuals in the UK will have the disease by 2010. People with diabetes have a high risk of cardiovascular disease—coronary heart disease is more prevalent, more extensive, and more diffuse. For all cardiovascular syndromes, the mortality is virtually doubled in patients with diabetes. Large clinical trials have provided clear evidence of the reduction in cardiovascular risk that can be achieved by treating hyperglycaemia as well as traditional risk factors, such as hypertension and hyperlipidaemia. The challenge now is for all health care professionals to implement the treatment guidelines.
Full Text
The Full Text of this article is available as a PDF (97.9 KB).
Figure 1 .
Effect of metformin in overweight patients. Adapted from UKPDS,4 with permission.
Figure 2 .
Data from the CAPRIE study showing higher rate of cardiovascular events (myocardial infarction, stroke, vascular death. and rehospitalisation for ischaemic events) in patients with diabetes. Adapted from Bhatt et al,15 with permission.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amos A. F., McCarty D. J., Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 (Suppl 5):S1–85. [PubMed] [Google Scholar]
- Bhatt Deepak L., Marso Steven P., Hirsch Alan T., Ringleb Peter A., Hacke Werner, Topol Eric J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002 Sep 15;90(6):625–628. doi: 10.1016/s0002-9149(02)02567-5. [DOI] [PubMed] [Google Scholar]
- Roper Nick A., Bilous Rudy W., Kelly William F., Unwin Nigel C., Connolly Vincent M., South Tees Diabetes Mortality Study Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care. 2002 Jan;25(1):43–48. doi: 10.2337/diacare.25.1.43. [DOI] [PubMed] [Google Scholar]
- Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410–418. doi: 10.1056/NEJM199908053410604. [DOI] [PubMed] [Google Scholar]
- Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
- Serruys Patrick W. J. C., de Feyter Pim, Macaya Carlos, Kokott Norbert, Puel Jacques, Vrolix Matthias, Branzi Angelo, Bertolami Marcelo C., Jackson Graham, Strauss Bradley. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Jun 26;287(24):3215–3222. doi: 10.1001/jama.287.24.3215. [DOI] [PubMed] [Google Scholar]